About Adcock Ingram Pharma Private Limited
Data last updated:
Adcock Ingram Pharma Private Limited is a private limited company based in Bengaluru, Karnataka, India, a subsidiary of Adcock Ingram Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 07 June 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24299KA2021PTC148184. Its GSTIN is 29AAVCA3052C1ZN (Karnataka).
The company has an authorised share capital of ₹71.46 Cr and a paid-up capital of ₹71.46 Cr. It is led by directors including Ammanna Chowdary Yarlagadda (Managing Director) and Pravin Vaidyanathan Iyer.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 41/42 Bommasandra Industrial Area Anekal Taluk, Bengaluru, Karnataka, India – 560099.
As per the financials filed for FY 2025, the company reported a revenue of ₹47.27 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹6.46 Cr (net margin -13.7%) and EBITDA of ₹8.35 Cr (EBITDA margin 17.7%). Revenue has grown at a compounded annual rate (CAGR) of 383% over three years.
The company has about 91 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹58 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medreich.com.
Company details
Contact details
Adcock Ingram Pharma Private Limited's registered office is in Bengaluru, Karnataka. Its website is medreich.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address41/42 Bommasandra Industrial Area Anekal Taluk, Bengaluru, Karnataka, India – 560099
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Adcock Ingram Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Adcock Ingram Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Adcock Ingram Pharma Private Limited, buy the company report.
Financials of Adcock Ingram Pharma Private Limited
FY 2025 filings availableAdcock Ingram Pharma Private Limited reported revenue of ₹47.27 Cr (up 3008% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 383% over three years. EBITDA rose 385% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹8.35 Cr | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹6.46 Cr | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 17.7% | |||
| Net Profit Margin | -13.7% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Adcock Ingram Pharma Private Limited, buy the company report.
Board of directors of Adcock Ingram Pharma Private Limited
Adcock Ingram Pharma has 7 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pravin Vaidyanathan Iyer Also directs: Adcock Ingram Limited, Relicare Tech Services Private Limited | Director | 07 Jun 2021 | 5 Years 5 Months | Current |
| Ammanna Chowdary Yarlagadda Also directs: Adcock Ingram Limited | Managing Director | 21 Sep 2022 | 4 Years 1 Months | Current |
| Kenshi Murase Also directs: Adcock Ingram Limited, Medreich Limited | Director | 11 Jun 2021 | 5 Years 5 Months | Current |
| Yudhveer Singh Also directs: Adcock Ingram Limited | Director | 24 Jan 2022 | 4 Years 9 Months | Current |
| Pankaj Garg | Director | 07 Jun 2021 | 5 Years 5 Months | Current |
| Dorette Neethling Also directs: Adcock Ingram Limited, Relicare Tech Services Private Limited | Director | 19 Feb 2025 | 1 Years 8 Months | Current |
Peer comparison
Adcock Ingram Pharma Private Limited is compared with the 8 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Kakatiya Industries Private Limited | ₹47.36 Cr (FY 2025) | 36.0% | Hyderabad, Telangana, India | |||
| Pon Pure Speciality Chemical Private Limited | ₹47.35 Cr (FY 2025) | 112.0% | Chennai, Tamil Nadu, India | |||
| Pest Mortem (India) Private Limited | ₹47.35 Cr (FY 2024) | -32.0% | Mumbai, Maharashtra, India | |||
| Averrile Surfactant Private Limited | ₹47.35 Cr (FY 2025) | 60.0% | Gandhi Nagar, Delhi, India | |||
| Taurus Chemicals Pvt Ltd | ₹47.32 Cr (FY 2025) | 10.0% | Hyderabad, Telangana, India | |||
| Adcock Ingram Pharma Private Limitedthis company | ₹47.27 Cr (FY 2025) | -₹6.46 Cr | -13.7% | 3008.0% | 91 | Bengaluru, Karnataka, India |
| Ezhil Chemical Private Limited | ₹47.23 Cr (FY 2021) | 86.0% | Nagapattinam, Tamil Nadu, India | |||
| Moti Lime Private Limited | ₹47.06 Cr (FY 2025) | -15.0% | Jodhpur, Rajasthan, India | |||
| Sanctus Global Formulations Limited | ₹47.05 Cr (FY 2025) | 32.0% | Chandigarh, India |
To see the full peer comparison of Adcock Ingram Pharma Private Limited, buy the company report.
Auditor
Adcock Ingram Pharma Private Limited is audited by S.R. Batliboi & Associates LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & Associates LLP | FY 2023 | 101049W/E300004 |
Shareholding
The shareholding of Adcock Ingram Pharma Private Limited is on record for 2 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Adcock Ingram Pharma Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Mar 2022 | 100553591 | Others | ₹58 Cr | Open |
To see the full charge records of Adcock Ingram Pharma Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Adcock Ingram Pharma Private Limited has 1 court case on record: 1 filed by Adcock Ingram Pharma. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Writ petition | Filed by the company | Pending |
To see the full case history of Adcock Ingram Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Adcock Ingram Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Adcock Ingram Pharma Private Limited has a workforce of 91 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 91 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 |
To see the full employee and EPFO history of Adcock Ingram Pharma Private Limited, buy the company report.
GST
Adcock Ingram Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAVCA3052C1ZN | Karnataka | Active | 24 Sep 2021 |
To see the full GST registrations and return filing status of Adcock Ingram Pharma Private Limited, buy the company report.
Recent activity
Adcock Ingram Pharma Private Limited has 15 board changes on record since 2021: 11 appointments and 4 cessations. The latest: Dorette Neethling was appointed as Director on 19 Feb 2025.
8 earlier events are in the company report.
Frequently asked questions
Adcock Ingram Pharma is an active private limited company based in Bengaluru, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 07 June 2021 (5+ years old) and is registered under CIN U24299KA2021PTC148184.
Adcock Ingram Pharma has 7 current directors:
- Ammanna Chowdary Yarlagadda - Managing Director
- Pravin Vaidyanathan Iyer - Director
- Kenshi Murase - Director
- Yudhveer Singh - Director
- Pankaj Garg - Director
- Dorette Neethling - Director
- Yasuhiro Nakagiri - Director
The latest financial statements of Adcock Ingram Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Adcock Ingram Pharma is 29AAVCA3052C1ZN, registered in Karnataka.
The CIN (Corporate Identification Number) of Adcock Ingram Pharma is U24299KA2021PTC148184. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Adcock Ingram Pharma has 1 court case on record: 1 filed by the company. 1 is pending.
Adcock Ingram Pharma was incorporated on 07 June 2021, making it 5+ years old. It is registered with the Registrar of Companies, Bangalore.
The peers of Adcock Ingram Pharma by revenue are Kakatiya Industries Private Limited, Pon Pure Speciality Chemical Private Limited, Pest Mortem (India) Private Limited, Averrile Surfactant Private Limited, Taurus Chemicals Pvt Ltd and 3 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dorette Neethling was appointed as Director on 19 Feb 2025. Shanthakumarie Pather ceased to be Director on 12 Feb 2025. Kensuke Hata ceased to be Director on 08 May 2024. Adcock Ingram Pharma has 15 board changes on record in total.
Adcock Ingram Pharma can be reached through the website medreich.com. Its registered office is in Bengaluru, Karnataka, India.
The registered office of Adcock Ingram Pharma is at 4142 Bommasandra Industrial Area Anekal Taluk, Bengaluru, Karnataka, India – 560099.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
